P634: Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore
ECCO '19 Copenhagen
2019
P635: Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P636: Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: real-world data in Germany
ECCO '19 Copenhagen
2019
P637: MMP-2 and -8 degraded and citrullinated-vimentin (VICM) correlates to disease activity in inflammatory bowel diseases
ECCO '19 Copenhagen
2019
P638: BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects
ECCO '19 Copenhagen
2019
P639: Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
ECCO '19 Copenhagen
2019
P640: Evaluation of dietetic services and the impact of diet on disease activity for patients with inflammatory bowel disease at Imperial College Healthcare NHS Trust
ECCO '19 Copenhagen
2019
P641: Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease
ECCO '19 Copenhagen
2019
P642: Anxiety and depression: beyond simple consequences of chronic inflammatory bowel diseases
ECCO '19 Copenhagen
2019
P643: Effectiveness of enhanced recovery after surgery in IBD: a propensity score matched cohort study in a single Italian centre
ECCO '19 Copenhagen
2019
P644: Mindfulness-based stress reduction in adult patients with active Crohn's disease: preliminary findings based on the subjective units of distress scale: an IIRN study
ECCO '19 Copenhagen
2019
P645: Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P646: Histological remission in patients with moderate-to-severe ulcerative colitis undergoing biological therapy: a single-centre experience
ECCO '19 Copenhagen
2019
P647: A pilot study: The importance of cognitive flexibility and flexibility in coping with stress for the quality of life in inflammatory bowel disease patients during biological therapy
ECCO '19 Copenhagen
2019
P648: Anti-TNF-α therapy, use of corticosteroids, and colectomy among paediatric and adolescent patients with ulcerative colitis: a nationwide study
ECCO '19 Copenhagen
2019
P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
ECCO '19 Copenhagen
2019
P651: Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience
ECCO '19 Copenhagen
2019